CDT Equity Inc.
Close on Oct 19, 2026
- Market cap
- $99.14K
- P/E (TTM)
- –
- Dividend yield
- –
About CDT Equity
Pharmaceutical Preparations, SIC 2834
CDT Equity Inc. is a clinical-stage biopharmaceutical enterprise focused on identifying, acquiring, licensing, developing, and commercializing clinical pharmaceutical assets. The organization seeks to advance drug candidates targeting significant unmet medical needs, utilizing artificial intelligence and collaborative decision-support technologies to optimize its development pipeline and clinical decision-making. Its activities include conducting research, managing preclinical and clinical programs, and evaluating targeted therapeutics under collaboration and licensing arrangements.
The company operates in the United States and maintains ongoing development relationships, consulting arrangements, and commercial agreements with international entities, including partners located in the United Kingdom. Its principal executive offices and corporate headquarters are situated at 4581 Tamiami Trail North, Suite 200, in Naples, Florida. The entity does not report physical retail stores or additional operational properties within the provided disclosure.
Summary of the business section of CDT Equity's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CDT Equity Inc.
- Headquarters
- Naples, FL
- Address
- 4851 Tamiami Trail North, Suite 200 34103
- Phone
- (646) 491-9132
- Website
- cdtequity.com
- Employees
- 4, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, New York, NY
Stock & identifiers
- Ticker
- CDT
- Other tickers
- CDTTW
- Exchange
- Nasdaq
- IPO date
- Mar 28, 2022
- Shares outstanding
- 1M, Aug 12, 2026
- Public float
- $55.20K, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Sep 29, 2026; 1-for-10 reverse, Jul 20, 2026; 1-for-25 reverse, Mar 27, 2026; 1-for-8 reverse, Oct 13, 2025; 1-for-15 reverse, May 20, 2025; 1-for-100 reverse, Mar 28, 2025; 1-for-100 reverse, Jan 27, 2025
- SEC CIK
- 1896212
- CUSIP
- 20678X114
- ISIN
- US20678X1147
- EIN
- 87-3272543
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Andrew Regan | Chief Executive Officer, Director | 5,699,306 |
| James Bligh | CFO, Director | 480,024 |
| David Tapolczay | Chief Executive Officer, Director | 2,003,324 |
| Ulrik K. Olsen | Director | 233,585 |
| Chele Chiavacci Farley | Director | 17,157 |
| Freda C. Lewis-Hall | Director | 38,810 |
| Simon Jeremy Fry | Director | 36,956 |
| Faith L. Charles | Director | 165,238 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of four full-time employees.”
Corporate history
Events identified from SEC filings